Project Grant F32AI186457
- The federal Project Grant award of $299,697 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel broad-spectrum antifungal agent targeting cell wall biosynthesis. The goal is to create a mechanistically unique inhibitor of the enzyme 1-3-D-glucan synthase (GS) that demonstrates potent and wide-ranging fungicidal activity, including against echinocandin-resistant...
- The Project Grant award of $170,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) is focused on the "Structure-Based Design of Antifungal Inhibitors Targeting the Glycosylphosphatidylinositol (GPI) Ethanolamine Phosphate Transferase, MCD4". The research aims to develop new antifungal agents with novel mechanisms of action to address emerging fungal pathogens and growing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,616 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Shy Therapeutics, LLC to develop a novel class of small molecule antifungal therapies. The project aims to identify and optimize new chemical compounds with potent activity against drug-resistant fungal strains such as Cryptococcus neoformans and Candida auris. Key objectives include using structure-activity relationship...
- This Project Grant award of $121,752 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into enhancing the efficacy of echinocandin antifungal drugs for treating invasive pulmonary aspergillosis (IPA). The project aims to investigate the role of the Septation Initiation Network (SIN) kinase cascade, particularly the terminal kinase SIDB, in regulating septation and echinocandin...
- This Project Grant award of $782,178 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop new antifungal agents against sterolglycoside enzymes found in fungal pathogens. The research team at Stony Brook University is using a high-throughput screening approach to identify inhibitors of the sterolglycoside enzymes SGL1 and SGLA, which are essential for the pathogenicity of Cryptococcus neoformans and Aspergillus...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training Program provides $308,925 to Chemia Biosciences, Inc. to develop computational technologies for discovering novel fungal natural products with potential antimicrobial and therapeutic applications. The primary goal is to create software that can predict the molecular structures of natural products encoded in fungal genomes, leveraging high-throughput...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the CFDA 93.855 Allergy and Infectious Diseases Research program, awarded a $300,000 Project Grant to Life Pharms Inc. on September 19, 2025. The grant supports the development of a novel antifungal drug, LP10581, to address the growing public health crisis of invasive, drug-resistant fungal infections. The project aims to further research and testing of this novel compound, which has shown promising in vitro and in vivo...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is focused on the development of novel benzyl-piperidine antifungal agents to treat intractable Mucorales infections. The $299,946 award to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, MA, aims to chemically optimize a lead series of benzyl-piperidine compounds to improve their...
CHEMOENZYMATIC TOTAL SYNTHESIS OF PENTAENE ANTIFUNGALS AND ANALOG DEVELOPMENT - PROJECT SUMMARY/ABSTRACT INFECTIONS CAUSED BY THE FUNGI CANDIDA AND ASPERGILLUS AFFECT MORE THAN ONE BILLION PEOPLE EACH YEAR. WHILE OFTEN NOT LIFE THREATENING, THESE INFECTIONS ARE MUCH MORE SEVERE WHEN THEY BECOME INVASIVE. INVASIVE INFECTIONS ARE EXCEPTIONALLY DEADLY IN PATIENTS UNDERGOING CHEMOTHERAPY OR WHO ARE OTHERWISE IMMUNODEFICIENT, AND CURRENT CLINICAL METHODS FOR THE TREATMENT OF INVASIVE FUNGAL INFECTIONS ARE INEFFECTIVE OR CAUSE COMPLICATIONS DUE TO OFF-TARGET TOXICITY. THIS RESULTS IN AN ANNUAL DEATH TOLL EXCEEDING 1.5 MILLION. AS SUCH, THE WORLD HEALTH ORGANIZATION (WHO) AND THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) HAVE IDENTIFIED RESEARCH SUPPORTING THE DEVELOPMENT OF NOVEL ANTIFUNGALS AS CRITICALLY IMPORTANT. THE RESEARCH PROPOSED IN THIS FELLOWSHIP WILL LEVERAGE CHEMOENZYMATIC TOTAL SYNTHESIS TO ACCESS PENTAENE ANTIFUNGALS IN A CONCISE AND MODULAR MANNER. THE CENTRAL HYPOTHESIS OF THIS RESEARCH PLAN IS THAT RATIONAL DESIGN OF NEW ANALOGS THAT CAN BE ACCESSED ONLY THROUGH CHEMICAL SYNTHESIS WILL AFFORD ANTIFUNGALS THAT RIVAL THE CURRENT CLINICAL STANDARD. THE PROPOSED SYNTHETIC STRATEGY RELIES ON AN ENZYMATIC ALDOL REACTION, BIDIRECTIONAL CHAIN EXTENSION, AND DESYMMETRIZATION TO DELIVER THE ALL-SYN BACKBONE PRESENT IN THE FILIPINS AND PENTAMYCIN. LATE-STAGE MACROCYCLIZATION WILL AVOID STABILITY CONCERNS ARISING FROM THE SENSITIVE PENTAENE MOTIF. FINALLY, CHEMOENZYMATIC OXIDATIONS WILL BE PERFORMED TO DELIVER THREE DIFFERENT PENTAENE NATURAL PRODUCTS. FURTHERMORE, WE PROPOSE A NOVEL ENZYMATIC MIX-AND-MATCH STRATEGY TO DELIVER DIFFERENT PARTIALLY OXIDIZED POLYENES THAT ARE NOT PRODUCED IN NATURE. THIS CHEMOENZYMATIC APPROACH WILL ENABLE THE DEVELOPMENT OF ANALOGS THAT CONTAIN MODIFICATIONS TO HYDROXYL GROUPS ALONG THE POLYOL BACKBONE, OR TO THE POLYENE MOTIF. THE FIRST CLASS OF ANALOGS IS DESIGNED TO PROBE HYDROGEN-BONDING TO ENHANCE ERGOSTEROL-BINDING SELECTIVITY AND AVOID HUMAN TOXICITY. THE SECOND CLASS IS DESIGNED TO INVESTIGATE P-STACKING, THEREBY MODIFYING SPECIFICITY AND STABILITY OF THE POLYENE ANTIFUNGALS. FINALLY, HYBRID ANALOGS THAT COMBINE THE MODIFICATIONS PRESENT IN BOTH CLASSES WILL BE SYNTHESIZED TO ACCESS THE IDEAL ANTIFUNGAL. ALL TOLD, ACCESS TO DOZENS OF ANALOGS THROUGH THE SAME ROUTE WILL ELUCIDATE STRUCTURE-ACTIVITY RELATIONSHIPS AND INFORM RATIONAL DESIGN OF NEW ANTIFUNGALS FOR THE BROADER SCIENTIFIC COMMUNITY. THE APPLICANT'S LONG-TERM GOALS ARE TO ENGAGE IN RESEARCH AT THE INTERFACE OF CHEMISTRY AND BIOLOGY TO SOLVE PROBLEMS THAT ARE CHALLENGING TO ADDRESS WITH EITHER DISCIPLINE INDEPENDENTLY. THIS FELLOWSHIP WILL ALLOW THE APPLICANT TO FURTHER IMPROVE THEIR SKILLS IN CHEMICAL SYNTHESIS WHILE LEARNING NEW TECHNIQUES IN ENZYMOLOGY, BIOLOGY, AND MEDICINAL CHEMISTRY. THE FELLOWSHIP WILL ALSO STRENGTHEN THE APPLICANT'S SKILLS IN MENTORING, TEACHING, AND COMMUNICATION SO THAT THEY CAN HAVE A SUCCESSFUL INDEPENDENT CAREER TRAINING JUNIOR SCIENTISTS IN ORGANIC CHEMISTRY. THIS WILL PROVIDE YOUNG SCIENTISTS WITH THE TOOLSET NECESSARY TO WORK AT THE INTERFACE OF ORGANIC CHEMISTRY AND OTHER IMPACTFUL FIELDS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/4/25 | ||
| Not listed | $0 | 8/11/25 | ||
| Not listed | $75.1k | 8/11/25 |